Abstract: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

Abstract: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

Abstract: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

Abstract: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

Abstract: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

Abstract: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinase activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

Abstract: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

Abstract: A fault identification system analyzes alarm information and the associated contextual information to identify the occurred faults. The contextual information is based on usecases, transactions, and functions associated with the electronic system under consideration. Multiple detectors that form part of knowledge repositories are used in the process of fault identification.

Abstract: Enterprises procure a large number of licenses of a large number of software packages. Software package inventory is one of the high cost items in these enterprises. It is necessary to contain this recurring expenditure on software packages by optimally utilizing the procured licenses. Disclosed is a system and method for maximizing software package license utilization. The system includes components for enabling managers of an enterprise to describe their need for software packages in project plans and users to use the software packages based on such plans. Further, the system also manages unplanned demands to use software packages and maintains a near-optimal inventory of licenses of software packages.

Abstract: The invention relates to molecules or molecular complexes which comprise binding pockets of angiotensin-converting enzyme-related carboxypeptidase or its homologues. The invention relates to a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. The invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. The invention relates to methods of using the structure coordinates to screen for and design compounds that bind to angiotensin-converting enzyme-related carboxypeptidase protein or homologues thereof. The invention also relates to crystallizable compositions and crystals comprising angiotensin-converting enzyme-related carboxypeptidase protein or angiotensin-converting enzyme-related carboxypeptidase protein complexes.

Abstract: A fault identification system consisting of multiple reasoning engines and the blackboard analyzes alarm information and the associated contextual information to identify faults. The contextual information associated with an alarm is derived by analyzing the alarm along four spaces, namely, transaction-space, function-space, execution-space, and signal-space. The reasoning engines associated with these spaces infer and/or validate the occurrences of faults. Transaction reasoning engine, using the associated knowledge repository, processes the generated alarms to infer and validate faults. Monitor reasoning engine, using the associated knowledge repository, processes domain specific monitor variables to infer faults. Execution reasoning engine, using the associated knowledge repository, processes execution specific monitor variables to infer and validate faults. Function reasoning engine, using the associated knowledge repository, reasons to infer and validate faults.

Abstract: An advertisement system that provides subscribers with the most relevant advertisements based on their individual purchase prediction of the various products and contextual information such as location, ongoing public events, festivals and personal events. The system customizes the advertisements to suit the audiovisual, language, and textual caption preferences of the subscribers. System provides for tracking of various promotional offers made to the subscribers from the time the offer is made to the time it is redeemed by the subscriber. System consists of methods to learn (a) purchase predictions (b) preferred streaming schedule and (c) the subscriber's preferences in terms of audiovisual aspects of the advertisements. Purchase prediction for individual subscriber is derived from historical purchase data by time series analysis and the influence of events such as co-purchases of other products and organized events such as sales exhibitions and festivals is derived based on Bayesian network models.

Abstract: An ultrasound transducer comprising an array of individual piezoelectric transducer elements mounted upon an improved backing comprising rigid polymeric or polymer-coated particles fused into a macroscopically rigid structure having remnant tortuous permeability to provide high acoustic attenuation and to permit fluid passage into the backing structure during fabrication.